Advaxis to Present at the Jefferies 2017 London Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that company management will participate in the Jefferies 2017 London Healthcare Conference taking place November 15-16, 2017 in London, UK. Anthony Lombardo, interim Chief Executive Officer of Advaxis, will present a corporate overview and an update on the clinical development pipeline and milestones on November 16th at 8:00 am (GMT).
Event: Jefferies 2017 London Healthcare Conference
Presentation Date: Thursday, November 16, 2017
Presentation Time: 8:00 a.m. GMT
Location: Waldorf Hilton (Aldwych) in London, UK
The webcast of Mr. Lombardo’s presentation can also be accessed via the Investors Relations section of the Company’s website at www.advaxis.com. The webcast will be archived for a period of time.
Now in its eighth year, the Jefferies London Healthcare Conference is the largest healthcare-dedicated conference in Europe. This year the conference will feature 350 participating companies, 1,400 attendees and 3,400 investor and business-to-business meetings. The event features leading public and private companies from the pharmaceuticals, biotechnology, generics, consumer health, animal health, medical technology and healthcare services sectors from the United States, Europe, Africa, Middle East, Latin America, Russia, India, Israel, China and Japan.
About Advaxis, Inc.
Advaxis, Inc., located in Princeton N.J., is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and pre-clinical development: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop and commercialize the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapies. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2016, which is available at http://www.sec.gov.
Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
Noelle Heber, 609-250-7575
Sr. Director Corporate Communications and Government Affairs
Stern Strategy Group
Brian Hyland, 908-325-3891
Rachel Auerbach, 908-325-3898
LHA Investor Relations
Anne Marie Fields, 212-838-3777
Source: Advaxis, Inc.
Released November 9, 2017